Table 1 The study examined the relationships between overall survival over a 2-year period and survival under 2 years, as well as various patient characteristics.
Patients (n = 30) | Follow ≤2 (n = 13) | Follow >2 (n = 17) | p value | |
|---|---|---|---|---|
n % | n % | n % | ||
Age, years | 53.0 (39.5–60.0) | 50.0 (37.5–61.5) | 54.0 (41.0–60.0) | 0.542 |
Age | 1.000 | |||
≤60 | 24 (80.0%) | 10 (76.9%) | 14 (82.4%) | |
>60 | 6 (20.0%) | 3 (23.1%) | 3 (17.6%) | |
Gender | 0.880 | |||
Male | 18 (60.0%) | 8 (61.5%) | 10 (58.8%) | |
Female | 12 (40.0%) | 5 (38.5%) | 7 (41.2%) | |
Tumor number | 0.698 | |||
Solitary | 22 (73.3%) | 9 (69.2%) | 13 (76.5%) | |
Multiple | 8 (26.7%) | 4 (30.8%) | 4 (23.5%) | |
Tumor size | 0.666 | |||
>3 cm | 7 (23.3%) | 4 (30.8%) | 3 (17.6%) | |
≦3 cm | 23 (76.7%) | 9 (69.2%) | 14 (82.4%) | |
Tumor occurrence | 0.290 | |||
Primary | 26 (86.7%) | 10 (76.9%) | 16 (94.1%) | |
Recurrence | 4 (13.3%) | 3 (23.1%) | 1 (5.9%) | |
Bevacizumaba | 0.030* | |||
No used | 14 (46.7%) | 9 (69.2%) | 5 (29.4%) | |
Used | 16 (53.3%) | 4 (30.8%) | 12 (70.6%) | |
DM | 1 (3.3%) | 0 (0.0%) | 1 (5.9%) | 1.000 |
HTN | 6 (20.0%) | 2 (15.4%) | 4 (23.5%) | 0.672 |
Follow montha | 27.9 (12.6–55.8) | 12.2 (7.0–15.2) | 47.4 (33.9–94.4) | <0.001** |
